Skyran Biologics Competitors and Similar CompaniesClear all

Skyran Biologics's competitors and similar companies include BIOTON, MannKind Corporation, Diasome and Antag Therapeutics.

	Skyran Biologics Skyran Biologics is a company engaged in treating diabetic retinopathy without intraocular injections.	BIOTON Bioton is a biotech company whose major therapeutic area is diabetes.	MannKind Corporation MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.	Diasome Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity.	Antag Therapeutics Antag Therapeutics is a preclinical-stage biotechnology company focused on developing therapies for dietary-related metabolic diseases.
Founding Date	Founding Date 2017	Founding Date 1989	Founding Date 1991	Founding Date 2004	Founding Date 2017
Type	Type Private	Type Public	Type Public	Type Private	Type Subsidiary
Tags	Tags Healthcare biotech diabetes drug development pharma	Tags Healthcare biotech diabetes drug development pharma	Tags Healthcare biotech diabetes drug development pharma	Tags Healthcare biotech diabetes drug development pharma	Tags Healthcare biotech diabetes drug development pharma
Locations	Locations HQ	Locations Macierzysz, PL HQ	Locations Westlake Village, US HQ Danbury, US	Locations Cleveland, US HQ	Locations København, DK HQ
Employees	Employees 3	Employees 361	Employees 39513% increase	Employees 1515% increase	Employees 20
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) zł282.5m (FY, 2025)	Revenue (est.) $349m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods zł157.1m (FY, 2025)	Cost of goods $26.8m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit zł128.4m (FY, 2025)	Gross profit $322.2m (FY, 2025)	Gross profit N/A	Gross profit (kr13.1m) (FY, 2021)
Net income	Net income N/A	Net income zł3.4m (FY, 2025)	Net income $5.9m (FY, 2025)	Net income N/A	Net income (kr14.9m) (FY, 2021)
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 200m	Total funding raised $ 42.9m	Total funding raised N/A